ATE431143T1 - Muscarin-rezeptor-agonisten - Google Patents

Muscarin-rezeptor-agonisten

Info

Publication number
ATE431143T1
ATE431143T1 AT01995477T AT01995477T ATE431143T1 AT E431143 T1 ATE431143 T1 AT E431143T1 AT 01995477 T AT01995477 T AT 01995477T AT 01995477 T AT01995477 T AT 01995477T AT E431143 T1 ATE431143 T1 AT E431143T1
Authority
AT
Austria
Prior art keywords
receptor agonists
independently selected
muscarine receptor
orand
coch3
Prior art date
Application number
AT01995477T
Other languages
English (en)
Inventor
William Messer
Yang Cao
Original Assignee
Univ Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toledo filed Critical Univ Toledo
Application granted granted Critical
Publication of ATE431143T1 publication Critical patent/ATE431143T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01995477T 2001-01-29 2001-12-10 Muscarin-rezeptor-agonisten ATE431143T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/772,143 US6376675B2 (en) 1999-01-22 2001-01-29 Muscarinic receptor agonists
PCT/US2001/047474 WO2002060444A1 (en) 2001-01-29 2001-12-10 Muscarinic receptor agonists

Publications (1)

Publication Number Publication Date
ATE431143T1 true ATE431143T1 (de) 2009-05-15

Family

ID=25094053

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01995477T ATE431143T1 (de) 2001-01-29 2001-12-10 Muscarin-rezeptor-agonisten

Country Status (9)

Country Link
US (2) US6376675B2 (de)
EP (1) EP1355646B1 (de)
JP (2) JP2004520382A (de)
AT (1) ATE431143T1 (de)
CA (1) CA2434839A1 (de)
DE (1) DE60138732D1 (de)
DK (1) DK1355646T3 (de)
ES (1) ES2327104T3 (de)
WO (1) WO2002060444A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
EP1734941A2 (de) 2004-03-25 2006-12-27 The Feinstein Institute for Medical Research Neurale staubinde
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2006073484A2 (en) 2004-12-27 2006-07-13 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CN101374836A (zh) * 2005-12-27 2009-02-25 托莱多大学 毒蕈碱激动剂及其使用方法
WO2008118326A1 (en) * 2007-03-23 2008-10-02 University Of Toledo Muscarinic agonists and methods of use thereof
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
JP2011520905A (ja) 2008-05-15 2011-07-21 ザ・ユニバーシティ・オブ・トレド 向知性剤としてのムスカリンアゴニスト
WO2009152392A2 (en) * 2008-06-11 2009-12-17 University Of Toledo Muscarinic agonists for neurological disorders and methods of making the same
CN102215909B (zh) 2008-11-18 2014-09-10 赛博恩特医疗器械公司 优化用于消炎刺激的电极放置的装置和方法
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
EP2440284B1 (de) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nervenmanschette mit tasche für einen bleifreien stimulator
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
EP2515996B1 (de) 2009-12-23 2019-09-18 Setpoint Medical Corporation Nervenstimulatoren und systeme zur behandlung von chronischer entzündung
WO2012149524A1 (en) 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255B1 (de) 2016-01-20 2025-12-31 Setpoint Medical Corporation Implantierbare mikrostimulatoren und induktive ladesysteme
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
EP3668402B1 (de) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagusnervstimulationsvorscreening-test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP4090424A4 (de) 2020-01-13 2024-02-21 The Feinstein Institutes for Medical Research Behandlung von blutung und blutungsstörungen durch hochintensive fokussierte ultraschallstimulation der milz
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
EP4466064A4 (de) 2022-01-20 2026-01-14 Setpoint Medical Corp Behandlung von entzündungserkrankungen
CN121605195A (zh) * 2023-08-03 2026-03-03 纽罗克里生物科学有限公司 合成方法
WO2025174424A1 (en) * 2024-02-16 2025-08-21 Terran Biosciences Inc. Analogs of xanomeline, analogs of trospium, and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
WO1993014089A1 (en) 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5718912A (en) 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US6096767A (en) 1999-01-22 2000-08-01 The University Of Toledo Muscarinic receptor agonists

Also Published As

Publication number Publication date
JP2010159274A (ja) 2010-07-22
US20030032658A1 (en) 2003-02-13
US20010036953A1 (en) 2001-11-01
EP1355646B1 (de) 2009-05-13
EP1355646A4 (de) 2004-06-16
WO2002060444A1 (en) 2002-08-08
ES2327104T3 (es) 2009-10-26
US6376675B2 (en) 2002-04-23
DE60138732D1 (de) 2009-06-25
JP2004520382A (ja) 2004-07-08
US6602891B2 (en) 2003-08-05
EP1355646A1 (de) 2003-10-29
CA2434839A1 (en) 2002-08-08
DK1355646T3 (da) 2009-08-17

Similar Documents

Publication Publication Date Title
DK1355646T3 (da) Muscariniske receptoragonister
EA200400794A1 (ru) Фармацевтическая композиция антагониста рецептора тахикинина в форме наночастиц
EP1423111A4 (de) Fxr-nr1h4-nuklearrezeptorbindende verbindungen
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
NO20033385L (no) Fuserte heterocykliske forbindelser
BR0017025A (pt) Antagonistas do receptor y5 do neuropeptìdeo y de imidazola substituìda
MY119118A (en) Thiophenopyrimidines
FI942381A0 (fi) Aryylisubstituoituja heterosyklisiä yhdisteitä
BR0007987A (pt) Composto, composição farmacêutica, e, processopara preparação de um composto
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
KR100366902B1 (ko) 섭스턴스 ｐ 길항제로서 피페리디닐아미노메틸트리플루오로메틸 시클릭 에테르 화합물
GB9716657D0 (en) Chemical compounds
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
BR0006371A (pt) Compostos de 1,4-dihidropiridina substituìdos com heteroarilas de 5 membros como antagonistas de bradicinina
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7
ATE121732T1 (de) Maleimidverbindungen und diese enthaltende fungizide.
EP1253139A3 (de) Multioligoanilinierte Fullerene
ATE293591T1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
DE69703725D1 (de) Tetrazolyl-substituierte Chinuclidine als Substanz P Antagonisten
SE9901884D0 (sv) Novel compounds their use and preparation
DK0824100T3 (da) Tricykliske piperidinylaminoforbindelser som substans P-antagonister

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties